# Lecture 19: Regulatory and Legal Frameworks

## ğŸ“‹ Overview

**Instructor:** Ho-min Park  
**Email:** homin.park@ghent.ac.kr | powersimmani@gmail.com

ì´ ê°•ì˜ëŠ” ì˜ë£Œ AI ì‹œìŠ¤í…œì˜ ê¸€ë¡œë²Œ ê·œì œ ë° ë²•ì  í”„ë ˆì„ì›Œí¬ë¥¼ í¬ê´„ì ìœ¼ë¡œ ë‹¤ë£¹ë‹ˆë‹¤.

---

## ğŸ¯ Learning Objectives

1. **FDA ê·œì œ ê²½ë¡œ ì´í•´** - 510(k), PMA, De Novo ë¶„ë¥˜ ë° AI/ML íŠ¹í™” ê²½ë¡œ
2. **êµ­ì œ ê·œì œ í”„ë ˆì„ì›Œí¬** - EU MDR/IVDR, CE ë§ˆí‚¹, ì£¼ìš” êµ­ê°€ë³„ ê·œì œ
3. **ë²•ì  ì±…ì„ êµ¬ì¡°** - AI ì˜ë£Œê¸°ê¸°ì˜ ì±…ì„ ì†Œì¬ ë° ë¦¬ìŠ¤í¬ ê´€ë¦¬
4. **ì‹œíŒ í›„ ê°ì‹œ** - PMS, ë¶€ì‘ìš© ë³´ê³ , ì»´í”Œë¼ì´ì–¸ìŠ¤ ê°ì‚¬
5. **ê·œì œ ì „ëµ ìˆ˜ë¦½** - íš¨ê³¼ì ì¸ ì‹œì¥ ì§„ì… ì „ëµ ë° ë¯¸ë˜ ì •ì±… ë°©í–¥

---

## ğŸ“š Lecture Contents

### Part 1: FDA Regulatory Pathways (Slides 03-10)
- FDA AI/ML ê·œì œ ê²½ë¡œ
- 510(k) Clearance - ì‹¤ì§ˆì  ë™ë“±ì„±
- PMA Approval - ê³ ìœ„í—˜ ê¸°ê¸°
- De Novo Classification - ì‹ ê·œ ê¸°ê¸°
- Software as Medical Device (SaMD)
- Predetermined Change Control Plan (PCCP)
- Clinical Validation Requirements

### Part 2: International Regulatory Frameworks (Slides 11-17)
- EU MDR/IVDR - ìœ ëŸ½ ì˜ë£Œê¸°ê¸° ê·œì •
- CE Marking - ì í•©ì„± í‰ê°€
- UK MHRA Guidelines - ë¸Œë ‰ì‹œíŠ¸ í›„ ê·œì œ
- Health Canada Requirements
- APAC Regulations - ì•„ì‹œì•„-íƒœí‰ì–‘ ê·œì œ
- International Harmonization Efforts (IMDRF)

### Part 3: Legal and Liability Issues (Slides 18-29)
- Liability Framework - AI ì±…ì„ êµ¬ì¡°
- Malpractice Insurance - ì˜ë£Œê³¼ì‹¤ ë³´í—˜
- Intellectual Property - ì§€ì ì¬ì‚°ê¶Œ
- Data Rights and Ownership - ë°ì´í„° ê¶Œë¦¬
- Clinical Trial Regulations - ì„ìƒì‹œí—˜ ê·œì •
- Post-Market Surveillance - ì‹œíŒ í›„ ê°ì‹œ
- Adverse Event Reporting - ë¶€ì‘ìš© ë³´ê³ 
- Compliance Auditing - ì»´í”Œë¼ì´ì–¸ìŠ¤ ê°ì‚¬
- Case Law Analysis - íŒë¡€ ë¶„ì„
- Regulatory Strategy - ê·œì œ ì „ëµ
- Future Policy Directions - ë¯¸ë˜ ì •ì±… ë°©í–¥

---

## ğŸ—‚ï¸ File Structure

```
/mnt/user-data/outputs/
â”œâ”€â”€ L19_index.html                              # ë©”ì¸ ì¸ë±ìŠ¤ í˜ì´ì§€
â”œâ”€â”€ L19_01_Title_Medical_AI_Regulation.html     # íƒ€ì´í‹€ ìŠ¬ë¼ì´ë“œ
â”œâ”€â”€ L19_02_Regulatory_Landscape.html            # ê·œì œ í™˜ê²½ ê°œìš”
â”œâ”€â”€ L19_03_Part1_FDA_Frameworks.html            # Part 1 ì‹œì‘
â”œâ”€â”€ L19_04_FDA_AI_ML_Pathway.html               # FDA AI/ML ê²½ë¡œ
â”œâ”€â”€ L19_05_510k_Clearance.html                  # 510(k) ì¸ì¦
â”œâ”€â”€ L19_06_PMA_Approval.html                    # PMA ìŠ¹ì¸
â”œâ”€â”€ L19_07_De_Novo_Classification.html          # De Novo ë¶„ë¥˜
â”œâ”€â”€ L19_08_Software_as_Medical_Device.html      # SaMD
â”œâ”€â”€ L19_09_Predetermined_Change_Control.html    # PCCP
â”œâ”€â”€ L19_10_Clinical_Validation_Requirements.html # ì„ìƒ ê²€ì¦
â”œâ”€â”€ L19_11_Part2_International_Regulations.html # Part 2 ì‹œì‘
â”œâ”€â”€ L19_12_EU_MDR_IVDR.html                     # EU ê·œì •
â”œâ”€â”€ L19_13_CE_Marking.html                      # CE ë§ˆí‚¹
â”œâ”€â”€ L19_14_UK_MHRA_Guidelines.html              # UK MHRA
â”œâ”€â”€ L19_15_Health_Canada_Requirements.html      # ìºë‚˜ë‹¤ ê·œì œ
â”œâ”€â”€ L19_16_APAC_Regulations.html                # APAC ê·œì œ
â”œâ”€â”€ L19_17_Harmonization_Efforts.html           # êµ­ì œ ì¡°í™”
â”œâ”€â”€ L19_18_Part3_Legal_Considerations.html      # Part 3 ì‹œì‘
â”œâ”€â”€ L19_19_Liability_Framework.html             # ì±…ì„ í”„ë ˆì„ì›Œí¬
â”œâ”€â”€ L19_20_Malpractice_Insurance.html           # ì˜ë£Œê³¼ì‹¤ ë³´í—˜
â”œâ”€â”€ L19_21_Intellectual_Property.html           # ì§€ì ì¬ì‚°ê¶Œ
â”œâ”€â”€ L19_22_Data_Rights_Ownership.html           # ë°ì´í„° ê¶Œë¦¬
â”œâ”€â”€ L19_23_Clinical_Trial_Regulations.html      # ì„ìƒì‹œí—˜ ê·œì •
â”œâ”€â”€ L19_24_Post_Market_Surveillance.html        # ì‹œíŒ í›„ ê°ì‹œ
â”œâ”€â”€ L19_25_Adverse_Event_Reporting.html         # ë¶€ì‘ìš© ë³´ê³ 
â”œâ”€â”€ L19_26_Compliance_Auditing.html             # ì»´í”Œë¼ì´ì–¸ìŠ¤ ê°ì‚¬
â”œâ”€â”€ L19_27_Case_Law_Analysis.html               # íŒë¡€ ë¶„ì„
â”œâ”€â”€ L19_28_Regulatory_Strategy.html             # ê·œì œ ì „ëµ
â”œâ”€â”€ L19_29_Future_Policy_Directions.html        # ë¯¸ë˜ ì •ì±…
â”œâ”€â”€ L19_30_Thank_You.html                       # ë§ˆë¬´ë¦¬ ìŠ¬ë¼ì´ë“œ
â””â”€â”€ L19_README.md                               # ì´ íŒŒì¼
```

---

## ğŸ¨ Design Specifications

- **Slide Size:** 960px Ã— 540px (16:9 ratio)
- **Font:** Aptos, 'Segoe UI', sans-serif
- **Primary Color:** #1E64C8 (Blue)
- **Accent Color:** #ff9800 (Orange)
- **Background:** White / Blue gradient (for title/part slides)

---

## ğŸš€ How to Use

1. **ë©”ì¸ í˜ì´ì§€ ì—´ê¸°:**
   - `L19_index.html` íŒŒì¼ì„ ë¸Œë¼ìš°ì €ì—ì„œ ì—´ì–´ ì „ì²´ ìŠ¬ë¼ì´ë“œ ëª©ë¡ì„ í™•ì¸í•˜ì„¸ìš”.

2. **ê°œë³„ ìŠ¬ë¼ì´ë“œ ë³´ê¸°:**
   - ê° HTML íŒŒì¼ì„ ì§ì ‘ ì—´ê±°ë‚˜, ì¸ë±ìŠ¤ í˜ì´ì§€ì—ì„œ í•´ë‹¹ ìŠ¬ë¼ì´ë“œë¥¼ í´ë¦­í•˜ì„¸ìš”.

3. **í”„ë ˆì  í…Œì´ì…˜ ëª¨ë“œ:**
   - ë¸Œë¼ìš°ì €ì˜ ì „ì²´ í™”ë©´ ëª¨ë“œ(F11)ë¥¼ ì‚¬ìš©í•˜ì—¬ í”„ë ˆì  í…Œì´ì…˜í•˜ì„¸ìš”.

4. **ìŠ¬ë¼ì´ë“œ íƒìƒ‰:**
   - Part êµ¬ë¶„: ìŠ¬ë¼ì´ë“œ 03, 11, 18ì—ì„œ ê° íŒŒíŠ¸ê°€ ì‹œì‘ë©ë‹ˆë‹¤.
   - ìˆœì°¨ì ìœ¼ë¡œ 01ë²ˆë¶€í„° 30ë²ˆê¹Œì§€ ì§„í–‰í•˜ì„¸ìš”.

---

## ğŸ“– Key Topics Covered

### ê·œì œ ê¸°ê´€
- **FDA (US)** - 510(k), PMA, De Novo
- **EMA/EU** - MDR, IVDR, CE Marking
- **MHRA (UK)** - UKCA Marking
- **Health Canada** - Agile Licensing
- **PMDA (Japan)**, **MFDS (Korea)**, **NMPA (China)**, **TGA (Australia)**, **HSA (Singapore)**

### ì£¼ìš” ê°œë…
- **SaMD (Software as Medical Device)**
- **PCCP (Predetermined Change Control Plan)**
- **IMDRF (International Medical Device Regulators Forum)**
- **UDI (Unique Device Identification)**
- **PMS (Post-Market Surveillance)**
- **MDR (Medical Device Reporting)**
- **GDPR, HIPAA, PIPEDA** - ë°ì´í„° ë³´í˜¸ ë²•ê·œ

### ì‹¤ë¬´ ê³ ë ¤ì‚¬í•­
- ìœ„í—˜ ê¸°ë°˜ ë¶„ë¥˜ ì‹œìŠ¤í…œ
- ì„ìƒ ê²€ì¦ ìš”êµ¬ì‚¬í•­
- ì‹œíŒ í›„ ê°ì‹œ ë° ë¶€ì‘ìš© ë³´ê³ 
- ë²•ì  ì±…ì„ ë° ë³´í—˜
- ì§€ì ì¬ì‚°ê¶Œ ë³´í˜¸
- ì»´í”Œë¼ì´ì–¸ìŠ¤ ê°ì‚¬

---

## ğŸ’¡ Key Takeaways

1. **ê·œì œëŠ” í™˜ì ì•ˆì „ì„ ìµœìš°ì„ ìœ¼ë¡œ í•©ë‹ˆë‹¤** - ëª¨ë“  ê·œì œ í”„ë ˆì„ì›Œí¬ì˜ í•µì‹¬ ëª©í‘œ
2. **êµ­ì œ ì¡°í™”ê°€ ì§„í–‰ ì¤‘ì…ë‹ˆë‹¤** - IMDRFë¥¼ í†µí•œ ê¸€ë¡œë²Œ í‘œì¤€í™” ë…¸ë ¥
3. **AI/ML íŠ¹í™” ê·œì œê°€ ë°œì „í•˜ê³  ìˆìŠµë‹ˆë‹¤** - ì ì‘í˜• ê·œì œ, PCCP ë“±
4. **íˆ¬ëª…ì„±ê³¼ ê²€ì¦ ê°€ëŠ¥ì„±ì´ í•µì‹¬ì…ë‹ˆë‹¤** - ë²•ì  ë¦¬ìŠ¤í¬ ì™„í™”ì˜ í•µì‹¬ ìš”ì†Œ
5. **ì§€ì†ì ì¸ ëª¨ë‹ˆí„°ë§ì´ í•„ìˆ˜ì…ë‹ˆë‹¤** - PMSë¥¼ í†µí•œ ì‹¤ì„¸ê³„ ì„±ëŠ¥ ì¶”ì 

---

## ğŸ”— Useful Resources

### Regulatory Bodies
- **FDA:** https://www.fda.gov/medical-devices
- **EMA:** https://www.ema.europa.eu/
- **MHRA:** https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency
- **Health Canada:** https://www.canada.ca/en/health-canada/services/drugs-health-products/medical-devices.html

### Guidelines & Standards
- **IMDRF:** http://www.imdrf.org/
- **ISO 13485:** Quality Management Systems for Medical Devices
- **ISO 14971:** Risk Management for Medical Devices
- **IEC 62304:** Software Life Cycle Processes

### Databases
- **FDA MAUDE:** https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfmaude/search.cfm
- **EUDAMED:** https://ec.europa.eu/tools/eudamed/

---

## ğŸ“§ Contact

**Instructor:** Ho-min Park  
**Email:** homin.park@ghent.ac.kr | powersimmani@gmail.com

For questions, clarifications, or further information about the lecture materials, please contact the instructor.

---

## ğŸ“„ License & Usage

ì´ ê°•ì˜ ìë£ŒëŠ” êµìœ¡ ëª©ì ìœ¼ë¡œ ì œì‘ë˜ì—ˆìŠµë‹ˆë‹¤. 
ìƒì—…ì  ì‚¬ìš©ì„ ì›í•˜ì‹œëŠ” ê²½ìš° ê°•ì‚¬ì—ê²Œ ë¬¸ì˜í•´ ì£¼ì„¸ìš”.

---

**Last Updated:** November 10, 2025  
**Version:** 1.0
